Shelter Mutual Insurance Co cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 73,900 shares of the biopharmaceutical company’s stock after selling 7,000 shares during the quarter. Gilead Sciences accounts for approximately 1.9% of Shelter Mutual Insurance Co’s holdings, making the stock its 27th largest position. Shelter Mutual Insurance Co’s holdings in Gilead Sciences were worth $5,987,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC grew its holdings in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares in the last quarter. Toronto Dominion Bank boosted its position in shares of Gilead Sciences by 19.0% in the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after acquiring an additional 75,364 shares during the last quarter. Finally, Fagan Associates Inc. boosted its position in shares of Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after acquiring an additional 845 shares during the last quarter. Institutional investors and hedge funds own 75.94% of the company’s stock.
Several equities research analysts recently issued reports on the stock. Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a research report on Wednesday, January 3rd. Oppenheimer assumed coverage on shares of Gilead Sciences in a research report on Thursday, October 5th. They issued a “market perform” rating on the stock. Mizuho raised their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Leerink Swann raised their target price on shares of Gilead Sciences from $87.00 to $89.00 and gave the stock a “market perform” rating in a research report on Thursday, October 5th. Finally, BMO Capital Markets decreased their target price on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and an average price target of $85.03.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $78.71 on Thursday. The firm has a market cap of $102,790.00, a P/E ratio of 8.95, a price-to-earnings-growth ratio of -1.58 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue was down 13.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.75 earnings per share. equities research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.64%. Gilead Sciences’s dividend payout ratio is currently 23.66%.
ILLEGAL ACTIVITY NOTICE: “Shelter Mutual Insurance Co Sells 7,000 Shares of Gilead Sciences, Inc. (GILD)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/01/11/shelter-mutual-insurance-co-sells-7000-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.